EXHIBIT 11.1
TITAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF COMPUTATION OF NET LOSS PER SHARE
THREE MONTHS ENDED
MARCH 31,
-------------------------------
1996 1997
-------------- ---------------
(unaudited)
Net loss $ (3,424,769) $ (13,158,566)
Deemed dividend upon conversion of preferred stock (5,431,871) -
-------------- ---------------
Net loss applicable to common stock $ (8,856,640) $ (13,158,566)
-------------- ---------------
-------------- ---------------
Weighted average shares of
common stock outstanding 8,824,159 12,897,703
-------------- ---------------
-------------- ---------------
Net loss per share $ (1.00) $ (1.02)
-------------- ---------------
-------------- ---------------
PRO FORMA
Net loss applicable to common stock $ (8,856,640) $ (13,158,506)
-------------- ---------------
-------------- ---------------
Calculation of shares outstanding for
Computing pro forma net loss per share:
Shares used in computing net loss per share 8,824,159 -
Adjusted to reflect the effect of the
Assumed conversion of preferred stock 1,092,091 -
-------------- ---------------
Shares used in computing pro forma net
loss per share 9,916,250 12,897,703
-------------- ---------------
-------------- ---------------
Net loss per share $ (0.89) $ (1.02)
-------------- ---------------
-------------- ---------------
14